Patient-reported outcomes with botulinum neurotoxin type A

Journal of Cosmetic and Laser Therapy

Volumn 9, Issue SUPPL. 1, 2007, Pages 32-37

  Carruthers, Alastair ^a,b   Carruthers, Jean ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b NONE   (Canada)

Author keywords

Botulinum neurotoxin type A; Facial Line Outcomes; Patient reported outcomes; Self Perception of Age

Indexed keywords

BOTULINUM TOXIN A; COSMETIC;

AGING; ARTICLE; ESTHETICS; FACE; FACIAL EXPRESSION; FACIES; HUMAN; OUTCOME ASSESSMENT; PATIENT SATISFACTION; PRIORITY JOURNAL; QUESTIONNAIRE; REJUVENATION; SELF REPORT; WRINKLE;

AGING; BOTULINUM TOXIN TYPE A; CLINICAL TRIALS AS TOPIC; COSMETIC TECHNIQUES; FACE; HUMANS; NEUROMUSCULAR AGENTS; PATIENT SATISFACTION; QUESTIONNAIRES; REJUVENATION; SELF CONCEPT;

EID: 34548819649     PISSN: 14764172     EISSN: 14764180     Source Type: Journal    
DOI: 10.1080/17429590701523752     Document Type: Article

References (20)

1. Sundaram M, Kavookjian J, Patrick JH, Miller LA, Madhavan SS, Scott VG. Quality of life, health status and clinical outcomes in Type 2 diabetes patients. Qual Life Res. 2007;16:165-77.
2. Bhosle MJ, Kulkarni A, Feldman SR, Balkrishnan R. Quality of life in patients with psoriasis. Health Qual Life Outcomes. 2006;4:35.
3. Brubaker L, Chapple C, Coyne KS, Kopp Z. Patient-reported outcomes in overactive bladder: importance for determining clinical effectiveness of treatment. Urology. 2006;68 2 suppl:3-8.
4. Coyne KS, Matza LS, Thompson C, Jumadilova Z, Bavendam T. The responsiveness of the OAB-q among OAB patient subgroups. Neurourol Urodyn. 2006;26:196-203.
5. Solish N, Benohanian A, Kowalski JW; on behalf of the Canadian Dermatology Study Group on Health-Related Quality of Life in Primary Axillary Hyperhidrosis. Prospective open-label study of botulinum toxin type A in patients with axillary hyperhidrosis: effects on functional impairment and quality of life. Dermatol Surg. 2005;31:405-13.
6. Khullar V, Chapple C, Gabriel Z, Dooley JA. The effects of antimuscarinics on health-related quality of life in overactive bladder: a systematic review and meta-analysis. Urology. 2006;68 2 suppl:38-40.
7. Carruthers JA, Lowe NJ, Menter MA, Gibson J, Nordquist M, Mordaunt J, et al.; for the BOTOX Glabellar Lines I Study Group. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol. 2002;46:840-9.
8. Carruthers A, Carruthers J. Prospective, double-blind, randomized, parallel-group, dose-ranging study of botulinum toxin type A in men with glabellar rhytids. Dermatol Surg. 2005;31:1297-303.
9. Ascher B, Zakine B, Kestemont P, Baspeyras M, Bougara A, Santini J. A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. J Am Acad Dermatol. 2004;51:223-33.
10. Carruthers JD, Lowe NJ, Menter MA, Gibson J, Eadie N; for the Botox Glabellar Lines II Study Group, Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines. Plast Reconstr Surg. 2003;112:1089-98.
11. Finn JC, Cox SE, Earl ML. Social implications of hyperfunctional facial lines. Dermatol Surg. 2003;29:450-5.
12. Coté TR, Mohan AK, Polder JA, Walton MK, Braun MM. Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases. J Am Acad Dermatol. 2005;53:407-15.
13. Carruthers A, Carruthers J. Long-term safety of cosmetic botulinum toxin type A: a review. Dermatol Surg. Submitted.
14. Sommer B, Zschocke I, Bergfeld D, Sattler G, Augustin M. Satisfaction of patients after treatment with botulinum toxin for dynamic facial lines. Dermatol Surg. 2003;29:456-60.
15. Cox SE, Finn JC, Stetler L, Mackowiak J, Kowalski JW. Development of the Facial Lines Treatment Satisfaction Questionnaire and initial results for botulinum toxin type A-treated patients. Dermatol Surg. 2003;29:444-9.
16. Beer KR. Comparative evaluation of the safety and efficacy of botulinum toxin type A and topical creams for treating moderate-to-severe glabellar rhytids. Dermatol Surg. 2006;32:184-97.
17. Carruthers A, Carruthers J, Dessain AS. Preliminary results with the Facial Lines Outcomes (FLO) questionnaire in the treatment of multiple upper facial rhytids with botulinum toxin type A: results from a single-center, dose-comparison, pilot study. J Am Acad Dermatol. Submitted.
18. Carruthers J, Carruthers A. Botulinum toxin type A treatment of multiple upper facial sites: patient-reported outcomes. Dermatol Surg. 2007;33 special issue:S10-17.
19. Fagien S, Cox SE, Finn JC, Werschler WP, Kowalski JW. Patient-reported outcomes with botulinum toxin type A treatment of glabellar rhytids: a double-blind, randomized, placebo-controlled study. Dermatol Surg. 2007;33 special issue:S2-9.
20. Finzi E, Wasserman E. Treatment of depression with botulinum toxin A: a case series. Dermatol Surg. 2006;32:645-50.